The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...

The FDA declined to approve SYD-101, a low-dose atropine formulation that would have been the first pharmaceutical treatment ...

Sydnexis, Inc., ( a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL ...

Privately-held Californian biopharma Sydnexis has announced that the US Food and Drug Administration (FDA) has issued a ...

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

In a cohort of over 1.2 million Taiwanese children followed up for at least 5 years, those with myopia had a higher risk for ocular problems than those without the condition. However, among children ...